Arcutis Biotherapeutics' Zoryve Shows Rapid Disease Clearance in Infant Atopic Dermatitis Trial

MT newswire2026/10/09 15:13

11:13 AM EDT, 10/09/2026 (MT Newswires) -- Arcutis Biotherapeutics (ARQT) said Friday it presented new Zoryve data on atopic dermatitis and plaque psoriasis, alongside research into the underlying mechanisms of seborrheic dermatitis, at two medical conferences. A phase 2 trial of investigational Zoryve 0.05% cream in infants aged 3 to under 24 months showed rapid disease clearance over four weeks, with no serious adverse events among the 101 participants. The treatment is under review by the US Food and Drug Administration, with a decision expected by Feb. 23, 2027. Separate analyses from phase 3 trials showed that Zoryve 0.3% foam and cream improved psoriasis symptoms and quality of life, including outcomes related to sexual function and personal relationships among patients with and without genital involvement, Arcutis said. Shares of the company were up nearly 5% in Friday trading. Price: 25.66, Change: +1.17, Percent Change: +4.78

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Dow Jones Top Energy Headlines at 12 AM ET: Oil Futures Slide As Market Holds Out Hopes for Middle East Diplomacy | Energy ...

Dow Jones•2026/11/09 05:00

United States Dollar Index remains subdued as lower oil prices ease inflation pressure

FXStreet•2026/11/09 04:54

Citi is bullish on the Indian stock market, expecting the Nifty Index to rise to 28,000 points by the end of 2027.

路透社•2026/11/09 04:06

Silver Price Forecast: XAG/USD rises to near $53.00 as lower oil eases inflation pressure

FXStreet•2026/11/09 03:39